Drug intelligence / Profile preview

IBI3022

Development stage: Preclinical
Lead developer: Innovent Biologics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI3022 is a bi-specific antibody-drug conjugate (ADC) developed by Innovent Biologics. It targets both B7-H4 (V-set domain-containing T-cell activation inhibitor 1) and Trop-2 (Tumor-associated calcium signal transducer 2), functioning as an inhibitor of both proteins. The drug is designed for the treatment of gynecologic cancers, particularly female genital neoplasms, and aims to offer improved efficacy and safety profiles compared to existing therapies. Preclinical studies have shown that IBI3022 has a favorable developability profile and is well-tolerated in animal models at high doses[1][7][2].

Targets

VTCN1 (V-set domain containing T cell activation inhibitor 1)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on IBI3022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI3022.

Explore the full profile